(NASDAQ: RVNC) Revance Therapeutics's forecast annual revenue growth rate of 30.24% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 37.5%, and while it is forecast to beat the US market's average forecast revenue growth rate of 10.08%.
Revance Therapeutics's revenue in 2024 is $234,040,000.On average, 5 Wall Street analysts forecast RVNC's revenue for 2024 to be $24,678,763,747, with the lowest RVNC revenue forecast at $24,073,615,337, and the highest RVNC revenue forecast at $25,211,576,633. On average, 5 Wall Street analysts forecast RVNC's revenue for 2025 to be $34,728,990,919, with the lowest RVNC revenue forecast at $32,383,467,437, and the highest RVNC revenue forecast at $35,899,591,416.
In 2026, RVNC is forecast to generate $45,812,733,948 in revenue, with the lowest revenue forecast at $40,271,744,574 and the highest revenue forecast at $48,218,860,485.